Back to search

Peptide record

TPDB92082

MELITTIIN Melittin Melittin monomer Mellitin Antibacterial Anticancer Antifungal Antiparasitic Antiviral Blood-Brain Barrier Cell-penetrating Peptides Hemolysis Neuropeptide Toxicity standard modified_plain modified
26 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92082
MELITTIIN Melittin Melittin monomer Mellitin
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Blood-Brain Barrier Cell-penetrating Peptides Hemolysis Neuropeptide Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides Neuroactive peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab AFP-GFuse Antifungipept CAFPdb dbAMP 3.0 i2APP AI4AVP DRAVP 2.0 BBPpredict CellPPD-MOD CPPsite3.0 APD_complete APD_hemolytic HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0 DBAASP
standard modified_plain
Yes
A 26-aa standard natural and modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
GIGAVLKVLTTGLPALISWIKRKRQQ-NH2
Physicochemical Analysis
C131H228N38O32
NDCEHMFY
L
2847.49
12.43
5
0
12
+5
1.42
0.273
135.00
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
5500
193.15
5
Residue Composition
number
2
A
2
R
0
N
0
D
0
C
0
E
2
Q
3
G
0
H
3
I
4
L
3
K
0
M
0
F
1
P
1
S
2
T
1
W
0
Y
2
V
Amino Acid Distribution
A: 2 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 2 G: 3 H: 0 I: 3 L: 4 K: 3 M: 0 F: 0 P: 1 S: 1 T: 2 W: 1 Y: 0 V: 2
Chemical Descriptors
26
C131H228N38O32
2847.49
12.43
+5
1.42
0.273
Amidation AMD
L
Cationic
Linear
Linear
Free
Anticancer Antimicrobial
FLAK peptides Synthetic peptide Natural component of bee venom Main component of honey bee venom
N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)O
Evidence Records 19 records
Evidence 1 Activity

Activity

LD50
LD50 =9 µg/ml
Anticancer
9 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 2 Activity

Activity

LD50
LD50 =23 µg/ml
Anticancer
23 µg/mL

Target

Colon Cancer
SW-480
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 3 Activity

Activity

LD50
LD50 =18 µg/ml
Anticancer
18 µg/mL

Target

Skin Cancer
BMKC
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 4 Activity

Activity

LD50
LD50 =25 µg/ml
Anticancer
25 µg/mL

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 5 Activity

Activity

LD50
LD50 =13 µg/ml
Anticancer
13 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 6 Activity

Activity

LD50
LD50 =35 µg/ml
Anticancer
35 µg/mL

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 7 Activity

Activity

IC50
IC50 =3.2 ± 0.1 µM
Anticancer
3.2

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
30-Min

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 8 Activity

Activity

IC50
IC50 =2.1 ± 0.1 µM
Anticancer
2.1

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
2-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 9 Activity

Activity

IC50
IC50 =1.8 ± 0.1 µM
Anticancer
1.8

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
4-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 10 Activity

Activity

IC50
IC50 =1.4 ± 0.1 µM
Anticancer
1.4

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 11 Activity

Activity

IC50
IC50= 1.4±0.1 µM
Anticancer
1.4

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
4-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 12 Activity

Activity

IC50
IC50= 3.2±0.1 µM
Anticancer
3.2

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
30-Min

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 13 Activity

Activity

IC50
IC50= 2.1±0.1 µM
Anticancer
2.1

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
2-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 14 Activity

Activity

IC50
IC50= 1.8±0.1 µM
Anticancer
1.8

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
4-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 15 Activity

Activity

IC50
IC50= 1.4±0.1 µM
Anticancer
1.4

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 16 Activity

Activity

IC50
IC50 = 1.84 ± 0.75 µg/ml
Anticancer
1.84

Target

Leukemia Cancer
K-562
Blood

Assay & Model

Sulforhodamine B assay
96-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2023
Evidence 17 Activity

Activity

Cell-penetrating Peptides

Target

Beta-Lactam Resistant And Wild-Type E. Coli Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L
Protein derived
Have membrane active potential
Membrane damage
In vitro
CCCCCCCCC
Evidence 18 Activity

Activity

Cell-penetrating Peptides

Target

Gastric Cancer Cell Lines (Nugc-3, Mkn-7, Mkn-74),

Source & Reference

CPPsite3.0
CPPsite3

Other

Non-natural residues Linear L Cationic
Protein derived
AlexaFluor 430 at C terminus
Nucleus
No difference in the amount of monomer and dimer of melittin peptides that localized in the cells after 30 as well as 60 min treatment
In vitro
Evidence 19 Activity

Target

Cutibacterium acnes

Source & Reference

DBAASP
Additional Detail Fields 1 fields
CCCCCCCCC